Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

Competing Interest Statement

Anna DeFazio has received a research grant from AstraZeneca, not directly related to the content of this manuscript. The other authors declare no conflicts of interest. Matthias W. Beckmann conducts research funded by Amgen, Novartis and Pfizer. Peter A. Fashing conducts research funded by Amgen, Novartis and Pfizer. He received Honoraria from Roche, Novartis and Pfizer.

Funding Statement

All funding support are reported in the Supplementary Material

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All study participants provided written informed consent and participated in research or clinical studies at the host institute under ethically approved protocols. The studies and their approving institutes are listed as a separate online Supplement (Ethics Statement)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes